1.
Embracing the European Regulation in The Netherlands: VGO implementation status, its threats and opportunities
2.
The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
3.
4.
5.